RSV Immunization for Babies in Gurgaon

RSV (Respiratory Syncytial Virus) is a highly contagious virus that causes cold-like symptoms in older children and adults but can be severe in infants. Early signs include congestion, runny nose, irritability, decreased appetite, and fever. In babies, RSV can progress to severe lung illnesses like bronchiolitis and pneumonia. RSV is the leading cause of hospitalisations in babies under 1 year—in fact, babies are hospitalised from RSV 16 times more than from the flu. Globally, RSV causes approximately 33 million lower respiratory infections annually.

Nirsevimab is a monoclonal antibody approved by CDSCO (India's drug regulator) in August 2024 for RSV prevention in infants, marketed as Beyfortus in India. It is NOT a vaccine—instead, it provides ready-made preventive antibodies that give your baby an extra layer of protection immediately. A single dose provides approximately 5 months of protection, covering the entire RSV season. Nirsevimab is recommended by the CDC, AAP, and IAP for all infants entering their first RSV season.

In India, RSV season typically runs from August to January, coinciding with the monsoon and winter months. Peak RSV activity is usually observed between September and December. This is the ideal time to ensure your baby is protected with nirsevimab immunization.

According to CDC, AAP, and IAP guidelines, RSV immunization with nirsevimab is recommended for all infants under 1 year of age entering their first RSV season. High-risk infants (premature babies, those with chronic lung disease, congenital heart disease, or weakened immunity) up to 24 months may also benefit from protection during their second RSV season. Consult with our pediatricians to determine if your baby is eligible.

A single dose of nirsevimab provides protection for approximately 5 months, which typically covers the entire RSV season. This is sufficient to protect your baby through the high-risk months from August to January.

Studies showed that nirsevimab was similar in safety to a placebo. Common side effects are mild and may include a rash (red or bumpy skin), pain, swelling, or a hard spot at the injection site. Serious allergic reactions are rare but possible—seek medical help immediately if your child shows facial swelling, difficulty breathing, or bluish skin tone. Our pediatricians will monitor your baby for a short period after administration.

Nirsevimab should not be given to infants with a history of serious allergic reactions to nirsevimab or any ingredient in the formulation. Additionally, inform our pediatricians if your child has bleeding or bruising problems, as an injection could cause issues. If your baby has previously received palivizumab in the same RSV season, they should not receive nirsevimab. Our team will review your baby's medical history to ensure safe administration.

Yes, nirsevimab can be safely administered alongside routine childhood vaccines. According to CDC, AAP, and IAP guidelines, co-administration with vaccines like DTaP, Hepatitis B, IPV, and others does not affect the efficacy or safety of either. This means your baby can receive RSV immunization during a regular vaccination visit.

Yes, premature babies are actually among the highest priority candidates for nirsevimab as they are at increased risk for severe RSV illness. Our pediatricians will assess your premature baby and recommend the appropriate timing for immunization.

Infant RSV immunization (nirsevimab) is given directly to babies after birth and provides immediate protection. The maternal RSV vaccine (Abrysvo) is given to pregnant women to pass antibodies to the baby before birth. Currently, the maternal RSV vaccine is not available in India, making nirsevimab the recommended option for RSV protection. Both approaches should not be used together for the same infant.

If your baby is still within the eligible age range and RSV season is ongoing, they can still receive nirsevimab. Contact KinderCure to discuss the best approach for your baby's situation.

Nirsevimab is given as a single intramuscular injection, typically in the thigh muscle for infants. The procedure is quick and performed by our experienced pediatric team in a comfortable, child-friendly environment.

Preventive antibodies (monoclonal antibodies) have been used as medicine since 1996, and preventive antibodies specifically for RSV infections have been given to babies for over 25 years. Studies showed that nirsevimab was similar in safety to a placebo, with common side effects being mild rash or injection site reactions.

Yes, nirsevimab helps prevent RSV-related bronchiolitis—a common and potentially serious lung infection in babies where the small airways become inflamed. RSV is the leading cause of bronchiolitis in infants. By providing ready-made antibodies against RSV, nirsevimab significantly reduces the risk of severe bronchiolitis and related hospitalisations.

You can book an RSV immunization (nirsevimab) appointment by messaging us on WhatsApp. Prior appointment is recommended as we ensure adequate stock and preparation for your baby's visit. You can also request a callback if you prefer to speak with our team.